Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (1877 HK)
Watchlist
207
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Stella International
•
03 Jul 2024 06:30
HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September
There could be nearly 80 adds/deletes for the HSCI in September. That will trigger changes to the Southbound Stock Connect list and increase flows...
Brian Freitas
Follow
189 Views
Share
bullish
•
Shanghai Junshi Biosciences
•
17 Dec 2023 20:47
A/H Premium Tracker (To 15 Dec 23): Time To Go Long Hs Vs As.
A/H Premiums reached their highest average (arithmetic - not the HS Index) in a year on Monday. And then turned. Overseas liquidation feels...
Travis Lundy
Follow
601 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
13 Apr 2023 09:12
[Junshi Biosciences (1877 HK) TP Change]: Medium to near Term Outlook Is Still Cloudy at Best
We continue to view JUNSHI’s Phase III pipeline, consisting of Senaparib (JS109/IMP4297)(PARP), Ongericimab (JS002)(PCSK9), Bevacizumab...
Blue Lotus Research Institute
Follow
339 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
03 Sep 2023 09:06
China Healthcare Weekly (Sep.1) - China's New IPO Reform, Financing Environment, Junshi Biosciences
CSRC issued new policies related to IPO reform in China.As IPO rules in A-share face adjustments, fundraising ecology will change.Junshi is far...
Xinyao (Criss) Wang
Follow
422 Views
Share
bullish
•
Innovent Biologics Inc
•
04 Apr 2022 07:57
Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and...
Xinyao (Criss) Wang
Follow
293 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.1
x